Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Lenacapavir Injection Clear all

Conditions: HIV-1-infection
Interventions: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 47
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 42 more

Conditions: HIV Infections
Interventions: TAIL-PrEP for patients discontinuing cab-LA, TAIL-PrEP for patients considering discontinuing cab-LA, TAIL-PrEP for patients considering discontinuing LEN; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Up to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 6 more

Conditions: HIV Pre-exposure Prophylaxis
Interventions: Lenacapavir Injection, Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 339 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 21 more

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more

Conditions: HIV Infections
Interventions: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Timeline: 2026 – 2029
U.S. locations: 39
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more

Conditions: HIV-1 Infection
Interventions: Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 29
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 25 more

Conditions: HIV Prevention, HIV Pre-exposure Prophylaxis, HIV Prevention Program, HIV Prevention and Care, HIV Pre-exposure Prophylaxis Use
Interventions: Lenacapavir long-acting; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 35
States / cities: Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more

Conditions: Human Immunodeficiency Virus
Interventions: Lenacapavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Cabotegravir long-acting, Lenacapavir long-acting; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Long Beach, California

Conditions: HIV-1 Infection
Interventions: Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab, Zinlirvimab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 19 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 253 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Conditions: HIV Pre-exposure Prophylaxis Use
Interventions: Choice of follow up, Follow up via standard clinic; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: HIV Treatment, HIV Prevention
Interventions: At Home Self-Collections; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV-1-infection
Interventions: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 12
States / cities: Torrance, California • New Haven, Connecticut • Ft. Pierce, Florida + 8 more

Search by objective public record fields.

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

The TAIL-PrEP Study

Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP Persistence

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment